Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
Page 2

Furthermore, it is also noted that suitable bioequivalence methods are lacking for many generic ophthalmic formulations, including suspensions and emulsions. Therefore an investigation of the relationship between various physicochemical properties and their effect on ocular bioavailability will help the FDA in establishing guidelines for the determination of bioequivalence of ophthalmic suspensions and emulsions.

The scope of the program will cover two types of inquiries:

a) In vitro study – Formulations with different physicochemical properties are manufactured using a selected steroid and characterized in vitro. Drug release and stability tests are conducted to understand how differences in physicochemical properties may affect ocular bioavailability.

b) In vivo study – Formulations selected based on the results of the in vitro study are tested in an animal model. A pharmacokinetic study should be conducted by assessing the ocular distribution of the steroid in various eye tissues and organs at various time points.

In order to support these initiatives, the Food and Drug Administration is set to administer funds in the amount of $400,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The United States Department of Health and Human Services, the mother agency funding the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program, is country's premiere agency for protecting the health of all Americans and providing essential human services, especially to those who medically challenged and vulnerable.

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---

Rheumatic Diseases Research Core Centers Project
The National Institutes of Health, in close cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has established a program entitled Rheumatic Diseases Research Core Centers Project wherein they intend to solicit applications for the development of Research Core Centers concentrating on rheumatic diseases.

---

National Institutes of Health: Expanding the Encyclopedia of DNA Elements in Human and Model Organisms
The National Institutes of Health, in cooperation with the National Human Genome Research Institute, has established a funding opportunity to support the Expanding the Encyclopedia of DNA Elements in Human and Model Organisms project.

---

Cancer Research Network: a Research Resource within Health Care Delivery System
In cooperation with the National Cancer Institute, the National Institute of Health has recently announced a funding opportunity to support the Cancer Research Network(CRN) in its quest in reshaping the its organization to become a more broader resource for cancer researchers.

---